Biogen stock tumbled Thursday — pulling Prothena stock down — on mixed test results for an updated version of its Alzheimer's treatment. The post Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatment appeared first on Investor's Business Daily.
#biogen #prothena